Group items tagged

The Department of Health and Social Care (DHSC) has introduced a new prescription pre-payment certificate (PPC) for Hormone Replacement Therapy (HRT) which is said to benefit around 400,000 women who suffer from negative symptoms of the menopause in England. PPC will be rolled-out from 1 April and it reduce the HRT costs to less than £20 a year. Women prescribed HRT - the main treatment for menopause symptoms - will have access to a new scheme enabling access to a year's worth of menopause prescription items for the cost of two single prescription charges (currently £18.70). As part of commitments to reduce the cost of HRT for menopausal women, the prescription PPC will be valid for 12 months. It can be used against a list of HRT prescription items, and a patient can use this against an unlimited number of HRT items, such as patches, tablets and topical preparations. There will be no limit to how many times the certificate can be used while it is valid. "The introduction of the certificate delivers one of our year one priorities for the Women's Health Strategy for England. Published last summer, the strategy sets out an ambitious new agenda for improving the health and wellbeing of women and girls and to improve how the health and care system listens to women. Menopause was announced as a priority area within the strategy," said DHSC.

The Department of Health and Social Care (DHSC) has issued Serious Shortage Protocols (SSPs) on three HRT medicines to limit dispensing supply to three months. To ensure women across the UK will be able to more reliably access HRT products SSPs has been issued on the supply of Oestrogel, Ovestin cream and Premique Low Dose. DHSC stated, "Women who have a prescription for more than three months but are only able to access three months' supply will not have to pay an additional prescription charge." "This means women will not incur any additional costs. Imposing a three month limit will mean more women are able to access the medication they want. Any woman who is worried about access to HRT or is unable to access HRT should speak to her GP." Recently, Vaccine Taskforce Director General Madelaine McTernan has been appointed to spearhead a new HRT Supply Taskforce, applying lessons learned from the successful procurement seen during the Covid vaccination programme to identify ways to support the HRT supply chain ensuring it can meet both short and long term demand. The move will save time for patients as well as pharmacists and prescribers who are working tirelessly to tackle the covid backlog.

The Department of Health and Social Care (DHSC) has included Tibolone 2.5mg tablets (Livial) and Prasterone 6.5mg pessaries (Intrarosa) to the list of Hormone Replacement Therapy (HRT). It has updated the June 2023 Drug Tariff (Part XVI) to include these additional HRT medicines for which patients will be able to purchase an HRT PPC. "HRT is the replacement of female sex hormones oestrogen and progesterone in women to control symptoms of the menopause. Some medicines that are converted or break down into oestrogen, progestogen or androgen hormones are prescribed for relief of menopausal symptoms. For the purposes of the HRT PPC these are included within this definition of HRT," said DHSC.

More than 500,000 women in England have benefitted from cheaper hormone replacement therapy (HRT) since the launch of the HRT prescription prepayment certificates (PPC) on 1 April last year, according to the Department of Health and Social Care (DHSC). HRT is the main treatment for negative menopause symptoms that can impact all areas of a woman's life. Introduced as part of the government's Women's Health Strategy, which made menopause a priority area, the HRT PPC reduced prescription costs to just £19.30 per year, helping patients save hundreds of pounds in prescription charges. The DHSC has confirmed that more than £11 million was saved by women using the PPC in the last nine months. Using the HRT PPC, patients can get a range of HRT items, including patches, tablets, and topical preparations at reduced prices, and they can use it many times as needed throughout the year.

The Royal Pharmaceutical Society (RPS) has welcomed the Health Secretary Sajid Javid's plan to appoint Hormone Replacement Therapy (HRT) tsar to tackle the medicine shortages. On Sunday (April 24) Sajid Javid told the Mail that he planned to tackle the problem (shortage of HRT medicine) by appointing a new HRT tsar with the role modelled on that of Kate Bingham, who successfully led the government's Covid vaccine taskforce. "The difficulties in accessing HRT medicine have unfairly impacted women's mental health," said RPS President, Professor Claire Anderson. "I look forward to working with this new champion for HRT and the Government on how we can better support women's health, building on the positive move to reduce prescription charges for HRT for women." Anderson also stressed that "the Government should now go further and end unfair prescription charges for patients in England altogether."

Cutting the red tape that blocks pharmacists to alter the HRT prescription could 'quickly fix' the problem of women unable to access their HRT medicines, the Royal Pharmaceutical Society (RPS) told Daily Mail. RPS has suggested that allowing pharmacists to prescribe alternative HRT treatment amid nationwide shortage of HRT medicine could help the women who are struggling to access these medicines. Thorrun Govind, chair of the English Pharmacy Board, told MailOnline 'changes in prescription rules need to be changed urgently.' She added, 'For the pharmacists on the ground, they need the ability to get rid of this bureaucracy. When you think about it - who's best able to offer an alternative - that tends to be the pharmacist.' MailOnline quoted Professor Claire Anderson, president of the Royal Pharmaceutical Society, as said, 'We welcome the Health Secretary meeting with key suppliers and manufacturers to find solutions to the current shortages. But cutting the red tape holding pharmacists back could provide a 'quick fix' that would allow 'women to access their HRT medicines more speedily'.

The new Hormone Replacement Therapy (HRT) prescription pre-payment certificate (PPC) has witnessed more than 37,000 purchases both via online website and in-person in pharmacies since its launch on Saturday (1 April). As of 12pm today (4 April), 37,240 HRT PPCs have been bought online and 501 in-pharmacy, totalling 37,741 certificates. Department of Health and Social Care (DHSC) estimated women have saved over £1.13 million in prescription charges for the year, with the average person saving £30 for a year's supply. The new prescription pre-payment certificate is also predicted to enable around 400,000 women to have cheaper access to menopause support. On the launch of the scheme on Saturday, the huge demand for the much-anticipated certificate meant some patients were unable to access the website on the morning of 1 April. "The NHS Business Service Authority has ensured that the site has been working, allowing thousands of women to continue to successfully purchase a prescription for a year's worth of hormone replacement therapy products which help treat the menopause," said DHSC. Minister for Women's Health Strategy, Maria Caulfield said: "Over 37,700 women have come forward to claim cheaper HRT this weekend alone, showing what happens when we listen to what women want.

Britain's health regulator is poised to announce that hormone replacement therapy (HRT) will be made available over the counter for the first time, the Daily Telegraph has revealed. The newspaper first reported on Tuesday (February 1) that watchdogs were set to propose a reclassification of the medication so women are able to access it in a pharmacy without a prescription. Every year, some 1.5 million women experience difficult menopausal symptoms, such as hot flushes, night sweats, sleep disturbance and a variety of emotional problems. But only a tenth of them are prescribed HRT, following a consultation with a GP or specialist. According to the newspaper, the latest proposal aims to improve convenience so that women are able to access HRT more easily, without needing a GP appointment.

The National Pharmacy Association (NPA) has asked the Secretary of State for Health and Social Care to convene a 'medicines supply taskforce', following weeks of problems with antibiotics supplies. The NPA's chief executive Mark Lyonette wrote a letter to Steve Barclay this week. It cited the precedent of the HRT Taskforce which this summer brought together representatives from across the supply chain after months of supply problems affecting women. "We strongly believe that this situation calls for a similar response from the government. It is imperative that we resolve this supply situation urgently and therefore we request that you convene a Medicines Supply Taskforce, with all the relevant stakeholders in the supply chain, to urgently discuss and agree practical solutions to address the disruptions to the supply of medicines. HRT and antibiotics are the most visible examples of a wider problem with medicines supply which needs to be addressed." NPA board members Olivier Picard and Reena Barai were among the stakeholders joining meetings convened by the HRT Taskforce this summer.

HRT or Hormone Replacement Therapy is a standard treatment for night sweats, hot flashes, irritability, vaginal dryness, and also results in changing the sleeping patterns. Apart from treating these uncomfortable conditions, HRT is also useful in reducing the chances of heart disease. But just like many other drugs, HRT therapies also have risks. Constant use of Hormone Replacement Therapy might cause breast cancer in women.

Women in the UK will be able to purchase Gina 10 mg vaginal tablets without prescription from September from their local pharmacies, announced the Medicines and Healthcare products Regulatory Agency (MHRA). The Hormone Replacement Therapy (HRT) product, Gina 10 microgram vaginal tablets (containing estradiol) are used for the treatment of vaginal symptoms such as dryness, soreness, itching, burning and uncomfortable sex caused by oestrogen deficiency in postmenopausal women aged 50 years and above who have not had a period for at least one year. The decision to reclassify these vaginal tablets follows a safety review by the MHRA, independent advice from the Commission on Human Medicines (CHM), and a public consultation. The UK regulator sought views from patients, pharmacists, prescribers and a wide range of stakeholders including the Royal College of Obstetricians & Gynaecologists, the Faculty of Sexual & Reproductive Healthcare, the British Pharmacopoeia Commission and the British Menopause Society.

Veoza, a non-hormonal treatment for menopause, has been made available on the high street for the first time in the UK. British pharmacy chain Superdrug on Thursday (1st February) announced the launch of the newly approved menopause medication, expanding its comprehensive portfolio of products and services to support menopausal women. Veoza is a prescription medication that is used to manage vasomotor symptoms, specifically hot flushes and night sweats, which affect up to 80 per cent of women during menopause, as estimated by experts. It is recommended for women who prefer not to or are unable to take hormone replacement. Perimenopausal, menopausal and postmenopausal women, aged 45-65 who are not on Hormone Replacement Therapy (HRT) or hormonal contraception, and are suffering from moderate to severe vasomotor symptoms, are eligible to take the medication, the retailer said in a release.

Period problems, women's health research and support for domestic and sexual abuse victims are among the government's priorities for women's health in 2024, which Health Secretary Victoria Atkins announced at the Women's Health Summit on Wednesday. Organised in central London, the event marked the second year of the landmark Women's Health Strategy for England. Victoria joined women's health champions to celebrate successes of strategy's first year and outlined plans for coming year, which also include improving maternity care and support for mothers who suffer birth trauma. Successes achieved over the strategy's first 12 months include reducing the cost of hormone replacement therapy (HRT) for nearly half a million women and the rollout of specialist women's health hubs in every local health area. A new dedicated women's health section of the NHS website was also created, providing updated information, advice and practical resources for women's health across the life course.